Rhythm Biosciences : Investor Presentation

Investor Presentation

5 April 2022 ASX:RHY

A transformative and predictive cancer diagnostics technology company

Disclaimer

This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings in this presentation.

This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. Rhythm makes no warranty or representation (express or implied) as to the accuracy, reliability or completeness of the information contained in this presentation. Specifically, several matters referred to in the presentation remain under investigation and are subject to change or even elimination, depending on further research and investigation. Further, any opinions (including any forward-looking statements) expressed in this presentation are subject to change without notice. Rhythm and its directors, officers, employees, advisers and agents shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions, information or matters (express or implied) arising out of, contained in or derived from or for any omissions from this presentation, except liability under statute that cannot be excluded.

This presentation, including the information contained in this disclaimer, does not form part of any offer, invitation or recommendation in respect of shares, or an offer, invitation or recommendation to sell, or a solicitation of any offer to buy, shares in the United States, or in any other jurisdiction in which, or to any person to whom, such an offer would be illegal.

This presentation may include forward-looking statements. Forward-looking statements are only predictions and are subject to known and unknown risks, uncertainties and assumptions, many of which are outside the control of Rhythm. Actual values, results or events may be materially different to those expressed or implied in this presentation depending on a range of factors. Given these uncertainties, recipients are cautioned not to place reliance on forward-looking statements. No representation or warranty (express or implied) is made by Rhythm or any of its directors, officers, employees, advisers or agents that any forecasts, projections, intentions, expectations or plans set out in this presentation will be achieved.

Introduction

Rhythm's initial product, ColoSTAT® is a simple, low-cost blood test for the early detection of colorectal cancer for global mass-market screening.

IP protection secured in all major international jurisdictions.

Commenced platform technology program for multiple / pan cancer targets.

ColoSTAT® Highlights

Disruptive and transformative technology

Significantly cheaper and easier to administer

Globally addressable markets

Performance better than market standard

Manufacturing & Patents secured

Initial revenues targeted for 2022

Company Overview

Capital Structure
ASX Code	RHY
Share Price (at 4 April 2022)	$1.76
Shares on Issue	214.1 M
Unlisted Options	16.8 M
Market Capitalisation	$376.8 M
Cash in bank (28 February 2022)	$10.8M
Top 20 Shareholders	46%

Share Price Chart

$7,000,000 $6,000,000 $5,000,000 $4,000,000 $3,000,000 $2,000,000 $1,000,000

$0

9-Mar-20

16-Mar-20

23-Mar-20

30-Mar-20

6-Apr-20

13-Apr-20

20-Apr-20

27-Apr-20

4-May-20

11-May-20

18-May-20

25-May-20

1-Jun-20

8-Jun-20

15-Jun-20

22-Jun-20

29-Jun-20

6-Jul-20

13-Jul-20

20-Jul-20

27-Jul-20

3-Aug-20

10-Aug-20

17-Aug-20

24-Aug-20

31-Aug-20

7-Sep-20

14-Sep-20

21-Sep-20

28-Sep-20

5-Oct-20

12-Oct-20

19-Oct-20

26-Oct-20

2-Nov-20

9-Nov-20

16-Nov-20

23-Nov-20

30-Nov-20

7-Dec-20

14-Dec-20

21-Dec-20

28-Dec-20

4-Jan-21

11-Jan-21

18-Jan-21

25-Jan-21

1-Feb-21

8-Feb-21

15-Feb-21

22-Feb-21

1-Mar-21

8-Mar-21

15-Mar-21

22-Mar-21

29-Mar-21

5-Apr-21

12-Apr-21

19-Apr-21

26-Apr-21

3-May-21

10-May-21

17-May-21

24-May-21

31-May-21

7-Jun-21

14-Jun-21

21-Jun-21

28-Jun-21

5-Jul-21

12-Jul-21

19-Jul-21

26-Jul-21

2-Aug-21

9-Aug-21

16-Aug-21

23-Aug-21

30-Aug-21

6-Sep-21

13-Sep-21

20-Sep-21

Volume

Board and Management

Otto Buttula

Chairman

• • Extensive financial, investment and biotech experience.

• • Co-Founder and CEO of IWL (ASX: IWL); Founder / former CEO of Investors Mutual.

• • Formerly a Director of Imugene (ASX: IMU) and Chairman of Investorfirst, now HUB (ASX: HUB).

• • Chairman of HITIQ (ASX: HIQ), Non-Executive Director of Oncosil Medical (ASX: OSL).

Glenn Gilbert CEO & Managing Director

•

Former	Head	of	Global	Sales,
Marketing	and	BD	at	Medical

•

Developments Int. (ASX: MVP). Various leadership positions at CSL (ASX: CSL).

•

Strong Legal, IP & Operational management.

•

Broad international business experience.

Trevor Lockett Executive-Director

• • Former Theme Leader Colorectal Cancer and Gut Health CSIRO.

• • Leader - Personalised Health GroupCSIRO.

• • Inventor on seven licensed patent families.

Lou Panaccio Non-Executive Director

• • Chairman Avita Medical (ASX: AVH).

• • Director Sonic Healthcare (ASX: SHL).

• • Chairman NeuralDX.

  commercially-

• • Non-executive Director,(ASX: ADR).

• • Non-executiveAdheriumDirectorHousing.

• • Former CEO Melb Pathology & Monash IVF.

Eduardo Vom Non-Executive Director

• • Co-Founder & Executive Director Planet Innovation.

• • Director Atmo Biosciences.

• • Former VP Innovation, Technologies.

  Genetic

  Unison

• • Various senior leadership positions Vision BioSystems.

27-Sep-21

4-Oct-21

$2.50

$2.00

$1.50

$1.00

$0.50

$0.00

11-Oct-21

18-Oct-21

25-Oct-21

1-Nov-21

8-Nov-21

15-Nov-21

22-Nov-21

29-Nov-21

6-Dec-21

13-Dec-21

20-Dec-21

27-Dec-21

3-Jan-22

10-Jan-22

17-Jan-22

24-Jan-22

31-Jan-22

7-Feb-22

14-Feb-22

21-Feb-22

28-Feb-22

7-Mar-22

14-Mar-22

21-Mar-22

28-Mar-22

4-Apr-22

Share Price

Rachel David

Non-Executive Director

• • Currently the Chief Executive Officer (CEO) of Private Healthcare Australia (PHA).

• • Senior Director Government Affairs, Policy and Market Access for Johnson & Johnson.

• • Various senior roles with McKinsey, CSL and Pfizer (formally Wyeth).